KPT-185 is an orally bioavailable selective inhibitor of CRM1 amd displayes potent antiproliferative properties at submicromolar concentrations,induced apoptosis (average 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines a

KP372-1 is a specific Akt inhibitor that blocks proliferation and induces apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro.

KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials.

KJ-Pyr-9 is a novel small-molecule inhibitor of c-Myc (Kd=6.5 ± 1.0 nM).

KIRA-7 is a small molecule inhibitor of IRE1α kinase/Rnase with IC50 of 0.11/0.22 uM, allosterically inhibits IRE1α RNase activity.

Kinetin (6-Furfuryladenine)

KIN-281 is a small molecule that inhibits multiple kinases including MELK and the non-receptor tyrosine kinase BMX with IC50 of 1.4 and 1.9 uM, respectively.

Kif15-IN-1 is a potent, selective inhibitor of KIF15 motility, can act synergistically with Eg5 inhibitors to impair cancer cell proliferation..

KI16 is a novel small molecules that inhibit STAT3-dependent transcription and function, interacts with the STAT3 SH2 domain.

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KH-CB19 is a potent and highly specific inhibitor of CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4) with IC50 of 20 nM (CLK1), displays almost 100-fold selectivity against the CLK3 isoform.

KH176 is a chemical entity derivative of Trolox and small molecule ROS-redox modulator, shows potential treatment for mitochondrial disorders.

KH-176 (KH176, Sonlicromanol) is a smal molecule ROS-redox modulator, effectively reduces increased cellular ROS levels and protects OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system.

KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM, shows no significant inhibitory effect on cathepsin B (IC50>10 uM).

KGP-420 is the water-soluble phosphate prodrug of KGP-94 in vivo studies, KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM.

KG-548 is an ARNT/TACC3 disruptor (IC50=25 uM) that selectively bind within the ARNT PAS (Per-ARNT-Sim) domain that recruits TACC3..

Ketoprofen (Actron) is a non-selective NSAID with IC50 of 0.5 μM and 2.33 μM for human recombinant COX-1 and COX-2, respectively.

Kelatorphan is a full inhibitor of enkephalin degrading enzymes.

KDU731 is a potent, selective parasite Cryptosporidium lipid kinase PI4K (phosphatidylinositol-4-OH kinase) inhibitor with IC50 of 25 nM, displays >50-fold selectivity window against the human PI4K IIIβ homologue.

KDS2010 (KDS-2010, KDS 2010) is a potent, highly selective, reversible Monoamine oxidase-B (MAO-B) inhibitor with IC50 of 7.6 nM.

KDM-IN-6 is a potent, highly selective and cell-active inhibitor of KDM2A/7A with IC50 of 0.16 and 0.19 uM,respectively.

KDM5-C49 is a potent, selective KDM5 inhibitor with IC50 of 25, 30 and 59 nM for KDM5A, B and C, respectively.

KDM5A covalent inhibitor N73 is the the isopropyl ester derivative of N71, an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481, >20-fold selectivity over KDM4A..

KDM5A covalent inhibitor N71 is an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481, >20-fold selectivity over KDM4A..

KCN1 (HIF inhibitor KCN1) is a small molecule inhibitor of the HIF-1 pathway, antagonizes HIF transcription in bioassay, blocks the p300/HIF-1α interaction, and exert potent anticancer activity in vitro and in vivo.

KCI807 (KCI-807) is a lead molecule that selectively disrupts ELK1-dependent promoter activation by wild-type and variant Ars (IC50=0.53 uM) without interfering with ELK1 activation by ERK.

KC01 is a potent and selective inhibitor of ABHD16A with IC50 of 90 nM for hABHD16A, 520 nM for mABHD16A.

KBP-5074 (KBP5074) is a novel non-steroidal, highly selective mineralocorticoid receptor antagonist for the treatment of hypertensive chronic kidney disease..

KB SRC 4 (c-Src-IN-4) is a potent, highly selective c-Src kinase inhibitor with Ki of 44 nM, does not inhibit c-Abl up to 125 uM, and binds to c-Src-TM (Q275G, C277Q, F278Y) with similar potency to that of wild-type c-Src.